ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020
Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Severe Acute Respiratory Syndrome Coronavirus 2 Diagnostic Tests for Border Screening During the Very Early Phase of Coronavirus Disease 2019 Pandemic: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Longitudinal serological response to SARS-CoV-2 among Rohingya refugees in cox's bazar, Bangladesh: implications for pandemic preparedness in humanitarian settings.Conflict and health · 2026Article
- Article
- Article
- Article
- Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery.Clinical and experimental immunology · 2024Article
- Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.Open forum infectious diseases · 2023Article
- The Fatal Clinical Outcome of Severe COVID-19 in Hospitalized Patients: Findings from a Prospective Cohort Study in Dhaka, Bangladesh.Medicina (Kaunas, Lithuania) · 2023Article
- SARS CoV-2 IgG positivity among the people in Dhaka city: An observation from the post vaccine period.Heliyon · 2023Article
- The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity.Medical microbiology and immunology · 2023Article
- Dependency of sanitation infrastructure on the discharge of faecal coliform and SARS-CoV-2 viral RNA in wastewater from COVID and non-COVID hospitals in Dhaka, Bangladesh.The Science of the total environment · 2023Article
- Projection of COVID-19 Positive Cases Considering Hybrid Immunity: Case Study in Tokyo.Vaccines · 2023Article
- Antibody response to different COVID-19 vaccines among the migrant workers of Bangladesh.Frontiers in immunology · 2023Article
- Smell Outcome and Seropositivity Titre in Post-COVID-19 Patients.ORL; journal for oto-rhino-laryngology and its related specialties · 2023Article
- Determining clinical biomarkers to predict long-term SARS-CoV-2 antibody response among COVID-19 patients in Bangladesh.Frontiers in medicine · 2023Article
- Longevity of Immunoglobulin-G Antibody Response Against Nucleocapsid Protein Against SARS-CoV-2 Among Healthcare Workers.Infection and drug resistance · 2023Article
- Asymptomatic versus symptomatic SARS-CoV-2 infection: a cross-sectional seroprevalence study.Tropical medicine and health · 2022Article
- Article
- Covishield vaccine induces robust immune responses in Bangladeshi adults.IJID regions · 2022Article
- Serological response to SARS-CoV-2 is attenuated in patients with inflammatory bowel disease and can affect immunization.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
objectivesStudies on serological responses following coronavirus disease-2019 (COVID-19) have been published primarily in individuals who are moderately or severely symptomatic, but there are few data from individuals who are mildly symptomatic or asymptomatic.
methodsWe measured IgG, IgM, and IgA to the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using enzyme-linked immunosorbent assay in mildly symptomatic (n = 108) and asymptomatic (n = 63) on days 1, 7, 14, and 30 following RT-PCR confirmation in Bangladesh and when compared with pre-pandemic samples, including healthy controls (n = 73) and individuals infected with other viruses (n = 79).
resultsMildly symptomatic individuals developed IgM and IgA responses by day 14 in 72% and 83% of individuals, respectively, while 95% of individuals developed IgG response, and rose to 100% by day 30. In contrast, individuals infected with SARS-CoV-2 but who remained asymptomatic developed antibody responses significantly less frequently, with only 20% positive for IgA and 22% positive for IgM by day 14, and 45% positive for IgG by day 30 after infection.
conclusionsThese results confirm immune responses are generated following COVID-19 who develop mildly symptomatic illness. However, those with asymptomatic infection do not respond or have lower antibody levels. These results will impact modeling needed for determining herd immunity generated by natural infection or vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.